Valuation models
price $558.88 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused438.69 – 725.22546.962% overvaluedDCF · Perpetuity growth · 10y509.04 – 856.30640.0013% undervaluedDCF · EBITDA exit · 5y450.29 – 489.76469.4919% overvaluedDCF · EBITDA exit · 10y520.16 – 608.50562.191% undervaluedP/E · peers363.44 – 655.92509.6810% overvaluedP/E · own history463.77 – 555.61509.7910% overvaluedPEG—324.8772% overvaluedEV/EBITDA · peers417.12 – 548.08482.6016% overvaluedEV/Revenue · peers237.33 – 566.68421.3433% overvaluedEarnings power value32.29 – 43.8936.871416% overvaluedWall St. consensus target—608.008% belowCost of capital (WACC)—7.11%—
DCF · Perpetuity growth · 5y leads for profitable growth — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
546.96
Vertex Pharmaceuticals closed at $558.88 — overvalued by 2% vs model.
438.69the model's range725.22
DCF · Perpetuity growth · 5y leads for profitable growth — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
36.87 – 640.00
Wall St. target
608.00 8% below
Above model, 1y
17 of 31 days
How it is valued
Valued asProfitable Growth
Moderate growth (~11% recent)High profitability (33% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.